Australia

Alpha Global partners with LIO to redefine Mental Health Care in Australia

New platform boosts patient experience and safety, reduces clinician burden, and unlocks operational insight across inpatient mental health hospitals SYDNEY, Aug. 14, 2025 /PRNewswire/ -- Alpha Global, a trusted provider of technology-driven solutions for healthcare and care providers inAustralia...

2025-08-14 11:00 2178

Australia's Prestigious Darwin Aboriginal Art Fair returns for its 19th Year, and you can access it online!

DARWIN, Australia, Aug. 7, 2025 /PRNewswire/ -- The world-renowned Darwin Aboriginal Art Fair (DAAF) returns to Larrakia Country in Darwin,Australia, and is online fromAugust 8 to 10 (2025), celebrating Australian Aboriginal and Torres Strait Islander art, design and culture.

2025-08-08 08:35 1938

X‑Design Tops Product Hunt with One-Click Lifestyle Product Photos

— A new AI tool that helps small Home Décor brands create realistic listing images without a studio SYDNEY, Aug. 7, 2025 /PRNewswire/ -- X‑Design , an AI product photo editor built specifically for small online sellers, was voted #1 Product of the Day on Product Hunt (A...

2025-08-08 03:01 1717

Vmake AI Talking Video Editor: The All-in-One Solution for Talking Videos, Empowering Diverse Creators

SYDNEY, Aug. 7, 2025 /PRNewswire/ -- Vmake , the pioneering AI-powered talking video editor by Starii Tech Pty Ltd, today unveiled a major upgrade to its innovative platform, uniquely tailored to creators of talking video content across various sectors. As the first-of-its-kind...

2025-08-08 03:00 1921

Kazia Therapeutics Announces $2 Million Private Placement at Premium to Market

SYDNEY, Aug. 1, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced that it has entered into a securities purchase agreement with certain established institutional investors for a private placement of equity securities (PIP...

2025-08-01 20:00 4724

A novel oral treatment for Alzheimer's: Actinogen's pivotal trial currently recruiting participants in the US

All 20 US trial sites are now open in the XanaMIA phase 2b/3 trial that is studying oral Xanamem® vs. placebo for 36 weeks, followed by an open label extension of active Xanamem for up to 24 months SYDNEY, July 22, 2025 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) is encouraging individu...

2025-07-22 20:00 1951

Co-PSMA trial: Recruitment successfully completed

SYDNEY, July 17, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the Co-PSMA (NCT...

2025-07-17 21:01 1994

Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial

SYDNEY, July 9, 2025 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA) is pleased to announce preliminary results from the first patient in its Phase1b trial evaluating a combination regimen of Paxalisib, pembrolizumab (Keytruda®), and standard chemotherapy after completing Cycle 1 (21 days) of d...

2025-07-09 20:00 3323

Mindsprint enhances ProcureSPRINT™ with Agentic AI to unlock up to 15% in procurement cost efficiencies

SINGAPORE, July 9, 2025 /PRNewswire/ -- Mindsprint , a technology firm offering purpose-built AI-led solutions to modernize enterprise operations, today announced significant advancements toProcureSPRINT™ , its enterprise-grade AI platform designed to optimize procureme...

2025-07-09 14:37 2079

Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001

Highlights: * Neurizon® Therapeutics and Elanco Animal Health enter into an exclusive global licensing agreement * Provides worldwide rights for Neurizon to utilise Elanco's intellectual property, providing exclusive access to an extensive package of non-clinical studies and manufacturing da...

2025-07-03 07:09 1919

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer's disease trial and interim analysis timeline

Interim analysis planned for January 2026 with final trial results in late 2026 Highlights: * With the 100th participant enrolled in the XanaMIA trial, the timeline for the planned interim analysis is confirmed forJanuary 2026 and the timeline for final results reconfirmed for late 2026 * An...

2025-06-30 20:30 1624

QBIOTICS REPORTS 80% OBJECTIVE RESPONSE RATE IN INJECTED TUMOURS IN STAGE 1 OF PHASE IIA CLINICAL TRIAL OF TIGILANOL TIGLATE FOR SOFT TISSUE SARCOMA

BRISBANE, Australia, June 25, 2025 /PRNewswire/ --   QBiotics CEO, Stephen Doyle, reflecting on Soft Tissue Sarcoma data * Positive data from Stage 1 of the Phase IIa clinical trial (QB46C-H07) evaluating QBiotics' small molecule, tigilanol tiglate in 11 (10 evaluable) patients with advanced S...

2025-06-25 18:05 1941

Academic friend or foe? Yugo research reveals how students supercharge their studies with AI

Despite academic advantages, substantial fears remain about AI's impact LONDON, June 19, 2025 /PRNewswire/ -- As universities grapple with how to effectively police AI, new Yugo research reveals the extent to which students are using it as a powerful study companion.

2025-06-19 05:33 2254

Largest Australian Health Insurer to Fund Innovative PTSD Treatment Program

PERTH, Australia, June 18, 2025 /PRNewswire/ -- Emyria Limited (ASX: EMD) ("Emyria", or the "Company") a leader in developing and delivering innovative mental health treatments, today announced a landmark partnership with Medibank, Australia's largest private health insurer. Under the multi-yea...

2025-06-18 20:00 2356

Polus holds €425 million initial close for third CLO equity fund

One of Europe's largest raises of its kind highlights Polus' leadership in the CLO and leveraged credit markets. LONDON, June 17, 2025 /PRNewswire/ -- Polus Capital Management ("Polus"), an investment management firm specialising in alternative credit strategies, is pleased to announce the initi...

2025-06-17 22:18 1956

Clarity enters a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with SpectronRx

Highlights * Clarity has entered into a Commercial Manufacturing Agreement with SpectronRx for64Cu-SAR-bisPSMA. * SpectronRx's facility in Indiana will provide on-demand commercial-scale manufacturing of both copper-64 and64Cu-SAR-bisPSMA under one roof and enables distribution to all 50 sta...

2025-06-17 21:04 1869

Ace Green Recycling and Enecell Announce Strategic Agreement to Advance Sustainable Battery Recycling in Australia

Ace to become Enecell's exclusive offtake partner for its lead battery recycling facility inPerth Commercial agreement is Ace's first in Australia, the world's largest lithium producer  HOUSTON, June 16, 2025 /PRNewswire/ -- Ace Green Recycling , Inc. ("Ace" o...

2025-06-16 20:00 1646

PATHOLOGICAL COMPLETE RESPONSE RECORDED IN PATIENT FROM ACCENT CANCER TRIAL

HIGHLIGHTS * A confirmed pathological complete response has been recorded in the ACCENT trial * A pathological complete response (pCR) is extremely rare in patients undergoing treatment for advanced pancreatic cancer * A pCR means that there are no signs of cancer in tissue examined by a p...

2025-06-16 19:00 1515

NUZ-001 Shows Promise in Zebrafish Model of Huntington's Disease

Highlights: * NUZ-001 and its active metabolite NUZ-001 Sulfone demonstrated significant neuroprotective effects in a zebrafish model of Huntington's disease * Treatment prevented hallmark developmental and morphological abnormalities, protected against neuronal cell death, restored delayed h...

2025-06-16 19:00 1563

SABRE topline results: Cu-64 SAR-Bombesin is effective in detecting prostate cancer recurrence in patients with negative SOC imaging

Highlights * Topline data from Clarity's diagnostic Phase II trial, SABRE, showed that 64 Cu-SAR-Bombesin was safe, well tolerated and effective at detecting prostate cancer in patients with biochemical recurrence (BCR) who are negative or equivocal on standard-of-care (SOC) scans, including pr...

2025-06-13 21:01 2405
123456 ... 49